Modern prostate cancer biomarkers. Prospects for EN2 in the prostate cancer diagnosis-Reference-Cited by-同舟云学术

Modern prostate cancer biomarkers. Prospects for EN2 in the prostate cancer diagnosis

Published:2020-11-19 Issue:3 Volume:16 Page:165-173
ISSN:1996-1812
Container-title:Cancer Urology
language:
Short-container-title:Onkourologiâ

Author:

Tarabayeva A. S.¹^ORCID,Zhubanturliyeva A. B.¹^ORCID,Okhas I. M.¹^ORCID

Affiliation:

1. Asfendiyarov Kazakh National Medical University

Abstract

Prostate cancer is one of the most common forms of malignant neoplasms in men. In this regard, it is relevant to search for diagnostic markers that allow the creation of inexpensive, effective tests for early diagnosis of the disease, predicting the risk of relapse and assessing the effectiveness of the therapy. Existing invasive methods for diagnosing prostate cancer present some difficulties for patients. This article discusses the diagnostic capabilities of tissue biomarkers of prostate cancer obtained by non-invasive methods.

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference55 articles.

1. https://www.wcrf.org/dietandcancer/cancer-trends/prostate-cancer-statistics.

2. Ishkinin E.I., Nurgaliev N.S., Zhylkaidarova A.Zh. et al. Molecular genetic methods for the diagnosis of aggressive forms prostate cancer. Meditsina (Almaty) = Medicine (Almaty) 2018;9(195):37-40. (In Russ.).

3. Strygina E.A., Medvedev V.L., Kurzanov A.N. Diagnostic and prognostic markers in prostate cancer. Sovremennyye problemy nauki i obrazovaniya = Modern Problems of Science and Education 2016;2. Available at: http://www.science-education.ru/ru/article/view?id=24439. (In Russ.).

4. Loeb S., Catalona W.J. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol 2014;6(2):74-7. DOI: 10.1177/1756287213513488.

5. Guazzoni G., Nava L., Lazzeri M. et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011;60: 214-22. DOI: 10.1016/j.eururo.2011.03.052.